{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"253"}]}],"title":"Patients with a DFS event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"253"},{"groupId":"OG002","value":"223"}]}],"title":"Recurrence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"title":"New Occurrence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"25"}]}],"title":"Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"718"},{"groupId":"OG001","value":"680"},{"groupId":"OG002","value":"699"}]}],"title":"Patients without events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"955"},{"groupId":"OG001","value":"960"},{"groupId":"OG002","value":"952"}],"units":"Participants"}],"description":"A disease-free survival (DFS) event was composed of a recurrence, a new occurrence of colorectal cancer or death due to any cause. Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator. Triggering events for DFS are reported; a patient can have both recurrence and a new occurrence of colon cancer.","groups":[{"description":"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m\\^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m\\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\\^2 bolus injection, and then as a 600 mg/m\\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\\^2 (alone), followed by 5-FU 400 mg/m\\^2 bolus injection, and 5-FU 600 mg/m\\^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).\n\nWeeks 25-48: Observation only.","id":"OG000","title":"FOLFOX4"},{"description":"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m\\^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m\\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\\^2 bolus injection, and then as a 600 mg/m\\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\\^2 (alone), followed by 5-FU 400 mg/m\\^2 bolus injection, and 5-FU 600 mg/m\\^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).\n\nWeeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).","id":"OG001","title":"FOLFOX4 + Bv"},{"description":"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m\\^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m\\^2 twice daily (equivalent to a total daily dose of 2000 mg/m\\^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).\n\nWeeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).","id":"OG002","title":"XELOX+Bv"}],"paramType":"NUMBER","populationDescription":"The primary population for efficacy analyses was the intent to treat population (ITT; all randomized patients) with stage III disease.","reportingStatus":"POSTED","timeFrame":"From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).","title":"Disease-free Survival in Stage III Cancer Patients - Number of Events","type":"PRIMARY","unitOfMeasure":"participants"}